The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kruglova L.S.

Central State Medical Academy of Department of Presidential Affairs

Lvov A.N.

Central State Medical Academy Department for Presidential Affairs of the Russian Federation;
Medical Research and Education Center of Lomonosov Moscow State University

Pushkina A.V.

Central State Medical Academy of Department of Presidential Affairs

Risks and predictors of the development of psoriatic arthritis in psoriasis and issues of the early administration of genetically engineered biological products

Authors:

Kruglova L.S., Lvov A.N., Pushkina A.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2020;19(3): 289‑296

DOI: 10.17116/klinderma202019031289

Read: 5936 times

Download PDF (RU)
Contact the author
Table of contents

RISKS AND PREDICTORS OF THE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS AND ISSUES OF THE EARLY ADMINISTRATION OF GENETICALLY ENGINEERED BIOLOGICAL PRODUCTS
RISKS AND PREDICTORS OF THE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS AND ISSUES OF THE EARLY ADMINISTRATION OF GENETICALLY ENGINEERED BIOLOGICAL PRODUCTS

To cite this article:

Kruglova LS, Lvov AN, Pushkina AV. Risks and predictors of the development of psoriatic arthritis in psoriasis and issues of the early administration of genetically engineered biological products. Russian Journal of Clinical Dermatology and Venereology. 2020;19(3):289‑296. (In Russ.)
https://doi.org/10.17116/klinderma202019031289

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Chro­nic hidradenitis suppurativa: morbidity patterns and patients’ routing in Saint-Petersburg. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):255-260
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Key specific tools for asse­ssment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):319-325
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
Diagnostic accu­racy of the aging males’ symptoms questionnaire for screening androgen defi­ciency in patients with psoriatic arthritis. Russian Journal of Preventive Medi­cine. 2025;(5):27-33
Syne­rgistic effi­ciency of preformed physical factors and dupi­lumab in the treatment of poly­pous rhinosinusitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):16-23
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Abstract:

The article is of an overview and contains up-to-date information on risk factors for the development of psoriatic arthritis in patients with psoriasis. In recent years, there has been a steady increase in the incidence of psoriatic arthritis, including severe forms, which lead to disability and incapacity. Psoriatic arthritis significantly affects the quality of life of patients, which is due to the clinical symptoms of the disease (pain, dysfunctions of the musculoskeletal system), and a significant economic burden (hospitalization, drugs, etc.). The data on the advisability of the early administration of genetically engineered biological products in order to prevent early disability and improve the quality of life of patients is report. According to the results of a 24-week PSARTROS study, in patients treated with secukinumab, resolving of the inflammation and the absence of structural progression of psoriatic arthritis were noted, which were persisted for 2 and 5 years of observation; the FUTURE 5 study indicates the absence of radiological signs of the progression of psoriatic arthritis in 90% of patients, as well as the achievement of ACR50 and PASI 100 in 50% of patients within 2 years of using secukinumab at a dose of 300 mg.

Keywords:

IL-17A
psoriasis
psoriatic arthritis
secukinumab
genetic engineering biological therapy

Authors:

Kruglova L.S.

Central State Medical Academy of Department of Presidential Affairs

Lvov A.N.

Central State Medical Academy Department for Presidential Affairs of the Russian Federation;
Medical Research and Education Center of Lomonosov Moscow State University

Pushkina A.V.

Central State Medical Academy of Department of Presidential Affairs

Received:

20.01.2020

Accepted:

23.03.2020

Close metadata

References:

  1. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015. Arthritis Rheumatol. 2016;68(5):1060-1071. https://doi.org/10.1002/art.39573
  2. Olivieri I, Padula A, D’Angelo S. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009;83:28-29.  https://doi.org/10.3899/jrheum.090218
  3. Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018;19(2):530.  https://doi.org/10.3390/ijms19020530
  4. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350. https://doi.org/10.1038/jid.2009.59
  5. Acosta Felquer M, FitzGerald O. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015;33(5 suppl 93):26-30. 
  6. Korotaeva TV. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Rheumatology Science and Practice. 2014;52(6):650-659. (In Russ.). https://doi.org/10.14412/1995-4484-2018-60-69
  7. Gladman DD, Ziouzina O, Thavaneswaran A, Chandran VJ. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. Rheumatol. 2013;40(8):1357-1359. https://doi.org/10.3899/jrheum.130163
  8. McGonagle DG, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012;225(2):100-109.  https://doi.org/10.1159/000341536
  9. Celis R, Cuervo A, Ramírez J, Cañete JD. Psoriatic Synovitis: Singularity and Potential Clinical Implications. Front Med (Lausanne). 2019;6:14.  https://doi.org/10.3389/fmed.2019.00014
  10. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr. Rheum. 2006;54(8):2665-2673.
  11. Coates L, Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthr Care Res. 2010;62(7):965-969.  https://doi.org/10.1002/acr.20155
  12. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72:736-740.  https://doi.org/10.1136/annrheumdis-2012-201706
  13. Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013;168:802-807.  https://doi.org/10.1111/bjd.12190
  14. Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014;71:649-655.  https://doi.org/10.1016/j.jaad.2014.05.010
  15. Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016;68:915-923.  https://doi.org/10.1002/art.39494
  16. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(2):37-39; discussion 40-41. 
  17. Taams LS, Steel KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453-466.  https://doi.org/10.1038/s41584-018-0044-2
  18. Abji F, Pollock RA, Liang K, et al. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol. 2016;68:2911-2916. https://doi.org/10.1002/art.39800
  19. Cretu D, Gao L, Liang K, et al. Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res. 2018;70:454-461.  https://doi.org/10.1002/acr.23298
  20. Cretu D, Liang K, Saraon P, et al. Quantitative tandem mass- spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. Clin. Proteomics. 2015;12:1.  https://doi.org/10.1186/1559-0275-12-1
  21. Manasson J, Shen N, Garcia Ferrer HR, et al. Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis. Arthritis Rheumatol. 2018;70:242-254.  https://doi.org/10.1002/art.40359
  22. Tito RY, Cypers H, Joossens M, et al. Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol. 2017; 69:114-121.  https://doi.org/10.1002/art.39802
  23. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population- based study. Arthritis Rheum. 2009;61:233-239.  https://doi.org/10.1002/art.24172
  24. Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225: 231-235.  https://doi.org/10.1159/000343607
  25. Castellanos-Gonzalez M, Joven BE, Sánchez J, et al. Nail involvement can predict enthesopathy in patients with psoriasis. J Dtsch Dermatol Ges. 2016; 14:1102-1107. https://doi.org/10.1111/ddg.12989
  26. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545-568.  https://doi.org/10.1016/j.rdc.2015.07.001
  27. Kyriakou A, Patsatsi A, Sotiriadis D. Detailed analysis of specific nail psoriasis features and their correlations with clinical parameters: a cross-sectional study. Dermatology. 2011;223(3):222-229.  https://doi.org/10.1159/000332974
  28. Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology. 2013;52:568-575.  https://doi.org/10.1093/rheumatology/kes324
  29. Hajiebrahimi M, Linder M, Hägg D, et al. Young patients with risk factors prevalent in the elderly — differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers. Clin Epidemiol. 2018;10:705-715.  https://doi.org/10.2147/CLEP.S164918
  30. Polachek A, Li S, Chandran V & Gladman DD. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res. 2017;69:1685-1691. https://doi.org/10.1002/acr.23174
  31. Eder L, Polachek A, Rosen CF, et al. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 2017;69:622-629.  https://doi.org/10.1002/art.39973
  32. Van Steenbergen HW, van Nies JA, Huizinga TW, et al. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Ann. Rheum. Dis. 2015;74:1225-1232. https://doi.org/10.1136/annrheumdis-2014-205522
  33. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71:1267-1772. https://doi.org/10.1136/annrheumdis-2011-201273
  34. Wu S, Li WQ, Han J, Sun Q & Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol. 2014;66:304-310.  https://doi.org/10.1002/art.38227
  35. Egeberg A, Khalid U, Gislason GH, et al. Association of psoriatic disease with uveitis: a Danish nationwide cohort study. JAMA Dermatol. 2015;151: 1200-1205. https://doi.org/10.1001/jamadermatol.2015.1986
  36. Lewinson RT, Vallerand IA, Lowerison MW, et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population- based study. J Invest Dermatol. 2017;137:828-835.  https://doi.org/10.1016/j.jid.2016.11.032
  37. Suruta N, Imafuku S & Narisawa Y. Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. 2017;44:1349-1352. https://doi.org/10.1111/1346-8138.13968
  38. Ogdie A, George MD, Gelfand J, et al. Weight change before and after diagnosis in patients with psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis [abstract]. Arthritis Rheumatol. 2017;69(10):2524.
  39. Siegel EL, Orbai AM, Ritchlin CT. Targeting extra- articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr. Opin. Rheumatol. 2015;27:111-117.  https://doi.org/10.1097/BOR.0000000000000155
  40. Carron P, Varkas G, Renson T, et al. High rate of drug- free remission after induction therapy with golimumab in early peripheral spondyloarthritis. Arthritis Rheumatol. 2018;70:1769-1777. https://doi.org/10.1002/art.40573
  41. Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol. 2014;10:212-228.  https://doi.org/10.1038/nrrheum.2014.6
  42. Burmester GR & Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338-2348. https://doi.org/10.1016/S0140-6736(17)31491-5
  43. Burgers LE, Allaart CF, Huizinga TWJ & Van der Helm-van Mil AHM. Brief report: clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: a trial of methotrexate versus placebo in undifferentiated arthritis as an example. Arthritis Rheumatol. 2017;69:926-931.  https://doi.org/10.1002/art.40062
  44. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060-1071. https://doi.org/10.1002/art.39573
  45. Van den Reek J, Seyger M, van Lumig P, et al. The journey of adult psoriasis patients towards biologics: past and present — Results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2018;32(4):615-623.  https://doi.org/10.1111/jdv.14684
  46. Faustini F, Simon D, Oliveira I, Kleyer A. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. 2016;75(12):2068-2074. https://doi.org/10.1136/annrheumdis-2015-208821
  47. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial [abstract]. Arthritis Rheumatol. 2018;70(10).
  48. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045-1050. https://doi.org/10.1136/annrheumdis-2013-204858
  49. Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012; 38:373-386.  https://doi.org/10.1016/j.rdc.2012.05.005
  50. Ritchlin CT, Colbert RA & Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957-970.  https://doi.org/10.1111/j.1529-8019.2008.01215.x
  51. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta- analysis. J Am Acad Dermatol. 2015;73:242-248.  https://doi.org/10.1016/j.jaad.2015.05.001
  52. Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate- to-severe plaque psoriasis. N Engl J Med. 2016;375:345-356.  https://doi.org/10.1056/NEJMc1610828
  53. Van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease- modifying anti- rheumatic drugs (COAST- V): 16 week results of a phase 3 randomised, double- blind, active- controlled and placebo- controlled trial. Lancet. 2018;392:2441-2451. https://doi.org/10.1016/S0140-6736(18)31946-9
  54. Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double- blind, placebo- controlled, proof- of-concept, dose- finding phase 2 study. Ann Rheum Dis. 2018;77:1295-1302. https://doi.org/10.1136/annrheumdis-2018-213328
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.